keyword
MENU ▼
Read by QxMD icon Read
search

hepatitis B antiviral therapy

keyword
https://www.readbyqxmd.com/read/28738457/-survey-of-economic-burden-of-hepatitis-b-related-diseases-in-12-areas-in-china
#1
Q S Ma, S Liang, H W Xiao, S X Zhang, G H Zhuang, Y H Zou, H Z Tan, J C Liu, Y H Zhang, A Q Xu, L Zhang, X X Feng, D S Hu, F Z Wang, F Q Cui, X F Liang
Objective: Less surveys on the economic burden of hepatitis B (HB)-related diseases have been conducted in China, so the socioeconomic harm caused by the diseases is not clear and the key parameters for economic evaluation of hepatitis B prevention and treatment are lacking. This study aimed to analyze the direct, indirect and intangible expenditures of hospitalized patients with HB-related diseases during hospitalization and during a year in different areas of China. Methods: The hospitals for infectious diseases and the large general hospitals in 12 areas in China were selected in the study...
July 10, 2017: Zhonghua Liu Xing Bing Xue za Zhi, Zhonghua Liuxingbingxue Zazhi
https://www.readbyqxmd.com/read/28738454/-development-of-markov-models-for-economics-evaluation-of-strategies-on-hepatitis-b-vaccination-and-population-based-antiviral-treatment-in-china
#2
P C Yang, S X Zhang, P P Sun, Y L Cai, Y Lin, Y H Zou
Objective: To construct the Markov models to reflect the reality of prevention and treatment interventions against hepatitis B virus (HBV) infection, simulate the natural history of HBV infection in different age groups and provide evidence for the economics evaluations of hepatitis B vaccination and population-based antiviral treatment in China. Methods: According to the theory and techniques of Markov chain, the Markov models of Chinese HBV epidemic were developed based on the national data and related literature both at home and abroad, including the settings of Markov model states, allowable transitions and initial and transition probabilities...
July 10, 2017: Zhonghua Liu Xing Bing Xue za Zhi, Zhonghua Liuxingbingxue Zazhi
https://www.readbyqxmd.com/read/28738453/-promoting-hepatitis-b-elimination-and-laying-emphasis-on-its-economics-evaluation
#3
S X Zhang
WHO has developed and issued global hepatitis B elimination program. Continuing hepatitis B immunization and conducting community based antiviral treatment for chronic hepatitis B are the most important strategies for hepatitis B elimination. According to the estimation of related cost by WHO, the cost of antiviral therapy would be very high. Great achievement has been made in hepatitis B immunization in China, but the prevalence of chronic hepatitis B is high. Elimination of hepatitis B needs a large amount of public resource, posing serious challenge to public health policy making...
July 10, 2017: Zhonghua Liu Xing Bing Xue za Zhi, Zhonghua Liuxingbingxue Zazhi
https://www.readbyqxmd.com/read/28736015/fibrosing-cholestatic-hepatitis-c-after-liver-transplantation-therapeutic-options-before-and-after-introduction-of-direct-acting-antivirals-our-experience-and-literature-review
#4
O Tronina, K Ślubowska, N Mikołajczyk-Korniak, E Komuda-Leszek, R Wieczorek-Godlewska, B Łągiewska, M Pacholczyk, W Lisik, M Kosieradzki, M Durlik
BACKGROUND: Cirrhosis caused by hepatitis C is the most common indication for liver transplantation. The most aggressive form of hepatitis C virus (HCV) relapse after liver transplantation is fibrosing cholestatic hepatitis C, which can be observed in 2% to 15% of recipients. METHODS: Double therapy with peg-interferon and ribavirin was characterized by low antiviral response, rapid fibrosis, and frequent graft failure within 1 year after surgery. RESULTS: Introduction of direct-acting antivirals for HCV treatment allows for more efficient therapy with less adverse reactions, including patients with fibrosing cholestatic hepatitis C...
July 2017: Transplantation Proceedings
https://www.readbyqxmd.com/read/28731907/oral-nucleos-t-ide-analogs-alone-after-liver-transplantation-in-chronic-hepatitis-b-with-preexisting-rt204-mutation
#5
James Fung, Tiffany Wong, Kenneth Chok, Albert Chan, Sui-Ling Sin, Tan-To Cheung, Wing-Chiu Dai, Kelvin Ng, Kevin Ng, Kwan Man, Wai-Kay Seto, Ching-Lung Lai, Man-Fung Yuen, Chung-Mau Lo
BACKGROUND: There is currently limited data regarding the use of oral antiviral therapy alone without HBIG for CHB patients with preexisting LAM-resistance (LAM-R) undergoing liver transplantation. METHODS: This is a cohort study determining the effectiveness and long-term outcome in this group of patients. RESULTS: Fifty-seven consecutive CHB patients with preexisting rt204 LAM-R mutations or virological load refractory to LAM undergoing liver transplantation were included, with a median follow-up of 73 months...
July 21, 2017: Transplantation
https://www.readbyqxmd.com/read/28725030/a-practical-model-evaluating-antiviral-cytokines-by-natural-killer-cells-in-treatment-na%C3%A3-ve-patients-with-chronic-hepatitis-b-virus-infection
#6
Xiaoyan Li, Yurong Gu, Xiaobo Guo, Lin Gu, Liang Zhou, Xiaojuan Wu, Xueqin Wang, Zania Stamataki, Yuehua Huang
Natural killer (NK) cells play a major role in anti-viral immunity as first line defense during hepatitis B infection, particularly in untreated patients whose T cells functions are profoundly impaired. Cytokine interferon (IFN)-γ and tumor necrosis factor (TNF)-α produced by NK cells are important anti-viral factors. However, there is lack of a quantifiable model to evaluate cytokine responses by NK cells. In this study, almost half of the patients (47.9%) beyond treatment criteria had high cytokine activity, although it was lower than those recommended for antiviral therapy (78...
July 19, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28723855/four-year-outcomes-after-cessation-of-tenofovir-in-immune-tolerant-chronic-hepatitis-b-patients
#7
Vincent Wai-Sun Wong, Aric J Hui, Grace Lai-Hung Wong, Rosita Suk-Yi Chan, Angel Mei-Ling Chim, Angeline Oi-Shan Lo, Henry Lik-Yuen Chan
GOALS: To study the long-term outcome after cessation of antiviral therapy in immune-tolerant patients. BACKGROUND: Experience in the treatment of immune-tolerant chronic hepatitis B is scanty. Some immune-tolerant patients may receive temporary antiviral therapy, such as for prevention of vertical transmission at pregnancy or prophylaxis for chemotherapy. STUDY: This was a follow-up study of a phase 2 trial at 2 centers. Immune-tolerant patients received tenofovir disoproxil fumarate and/or emtricitabine for 4 years and were followed for another 4 years after treatment cessation...
July 18, 2017: Journal of Clinical Gastroenterology
https://www.readbyqxmd.com/read/28709658/ngago-gdna-system-efficiently-suppresses-hepatitis-b-virus-replication-through-accelerating-decay-of-pregenomic-rna
#8
Zhuanchang Wu, Siyu Tan, Leiqi Xu, Lifen Gao, Haizhen Zhu, Chunhong Ma, Xiaohong Liang
Covalently closed circular DNA (cccDNA) in the hepatocytes nucleus is responsible for persistent infection of Hepatitis B virus (HBV). Current antiviral therapy drugs nucleos(t)ide analogs or interferon fail to eradicate HBV cccDNA. Genome editing technique provides an effective approach for HBV treatment through targeting viral cccDNA. Natronobacterium gregoryi Argonaute (NgAgo)-guide DNA (gDNA) system with powerful genome editing prompts us to explore its application in inhibiting HBV replication. Preliminary function verification indicated that NgAgo/EGFP-gDNA obviously inhibited EGFP expression...
July 12, 2017: Antiviral Research
https://www.readbyqxmd.com/read/28709657/detection-of-the-hepatitis-b-virus-hbv-covalently-closed-circular-dna-cccdna-in-mice-transduced-with-a-recombinant-aav-hbv-vector
#9
Julie Lucifora, Anna Salvetti, Xavier Marniquet, Laurent Mailly, Barbara Testoni, Floriane Fusil, Aurore Inchauspé, Maud Michelet, Marie-Louise Michel, Massimo Levrero, Pierre Cortez, Thomas F Baumert, François-Loic Cosset, Cécile Challier, Fabien Zoulim, David Durantel
Hepatitis B Virus (HBV) persists in infected hepatocytes as an episomal covalently-closed-circular DNA mini-chromosome, called cccDNA. As the main nuclear transcription template, HBV cccDNA is a key replication intermediate in the viral life cycle. Little is known about the mechanisms involved in its formation, maintenance and fate under antiviral therapies. This is mainly due to the lack of small immune-competent animal models able to recapitulate the entire HBV replication cycle, including formation of HBV cccDNA...
July 11, 2017: Antiviral Research
https://www.readbyqxmd.com/read/28706414/risk-of-hepatitis-b-reactivation-in-patients-treated-with-direct-acting-antivirals-for-hepatitis-c
#10
EDITORIAL
Ioanna Aggeletopoulou, Christos Konstantakis, Spilios Manolakopoulos, Christos Triantos
The recent introduction of direct-acting antiviral drugs (DAAs) for treatment of the hepatitis C virus (HCV) has greatly improved the management of HCV for infected patients. These viral protein inhibitors act rapidly, allowing HCV clearance and increasing the sustained virological response rates. However, hepatitis B virus (HBV) reactivation has been reported in HCV/HBV co-infected patients. Hepatitis B reactivation refers to an abrupt increase in the HBV and is well-documented in patients with previously undetected HBV DNA due to inactive or resolved HBV infection...
June 28, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28702738/impact-of-etiological-treatment-on-prognosis
#11
REVIEW
Chien-Wei Su, Ying-Ying Yang, Han-Chieh Lin
Portal hypertension (PHT) is a frequent and severe complication of cirrhosis. PHT may lead to the development of various complications with high mortality. Liver transplantation is the gold standard as a surgical curative treatment for end-stage liver disease. Theoretically, etiological treatment focusing on the pathophysiology of the underlying disease should be the objective of the nonsurgical management of cirrhotic PHT. Chronic viral hepatitis is the major etiology of cirrhosis and PHT. In cirrhotic patients with chronic hepatitis B virus infection, antiviral therapies can suppress viral replication, ameliorate hepatic inflammation, regress fibrosis, and restore liver functional reserve...
July 12, 2017: Hepatology International
https://www.readbyqxmd.com/read/28694862/primary-hepatic-marginal-zone-lymphoma-in-a-patient-with-chronic-hepatitis-c
#12
George S Gherlan, Razvan Stoia, Mihaly Enyedi, Camelia Dobrea, Petre I Calistru
Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) is a low-grade malignant lymphoma that appears frequently in the stomach, but other sites can also be involved: the intestinal tract, lungs, head, neck, skin, thyroid, breasts and liver. Recently, epidemiological evidences support the idea that there is an association between hepatitis C and B-cell non-Hodgkin lymphomas (that include MALT as a subtype). Primary non-Hodgkin lymphomas confi ned only to the liver are very rare (only 0...
September 2016: Mædica
https://www.readbyqxmd.com/read/28694000/boceprevir-based-triple-therapy-to-rescue-hcv-genotype-1-hbv-dually-infected-patients-refractory-to-peginterferon-plus-ribavirin-combination-therapy-in-taiwan
#13
Meng-Hsuan Hsieh, Ming-Lun Yeh, Tung-Hung Su, Ta-Wei Liu, Chuang-Feng Huang, Ching-I Huang, Shu-Chi Wang, Jee-Fu Huang, Chia-Yen Dai, Jia-Horng Kao, Wan-Long Chuang, Pei-Jer Chen, Chun-Jen Liu, Ming-Lung Yu
BACKGROUND/PURPOSE: The role of directly-acting antivirals (DAA)-containing regimens in the treatment of patients dually-infected with hepatitis C virus (HCV) and hepatitis B virus (HBV) remains unclear. The pilot study aimed to explore the safety and efficacy of a protease inhibitor, boceprevir, in combination with peginterferon/ribavirin for HCV genotype 1 (HCV-1)/HBV dually-infected patients refractory to prior peginterferon/ribavirin. METHODS: Twelve peginterferon-experienced patients dually-infected with HCV-1/HBV were assigned to receive boceprevir 800 mg, twice a day, plus peginterferon-α 2b 1...
July 7, 2017: Journal of the Formosan Medical Association, Taiwan Yi Zhi
https://www.readbyqxmd.com/read/28690451/new-direct-acting-antiviral-agents-and-immunomodulators-for-hepatitis-b-virus-infection
#14
Marion G Peters, Stephen Locarnini
Chronic hepatitis B (CHB) affects over 350 million individuals worldwide and is the most common cause of liver cancer. In the United States, CHB affects at least 2 to 3 million individuals, and current therapies can control the disease but not cure it. There are over 30 new molecules being studied in CHB in preclinical to phase 2 studies, targeting specific parts of the hepatitis B virus (HBV) life cycle and the host immune response. When discussing new therapies for CHB, it is critical to understand both the various phases of CHB and the life cycle of HBV...
June 2017: Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28689589/hepatitis-c-virus-associated-non-hodgkin-lymphomas-biology-epidemiology-and-treatment
#15
REVIEW
Gabriele Pozzato, Cesare Mazzaro, Valter Gattei
Eradication of hepatitis C virus (HCV) in indolent non-Hodgkin lymphomas (NHLs), especially in marginal zone lymphomas, determines the regression of the hematologic disorder in a significant fraction of cases. Because direct antiviral agents show an excellent profile in terms of efficacy, safety, and rapid onset of action, these drugs can be used in any clinical situation and in the presence of any comorbidities. To avoid the progression of the NHL, despite HCV eradication, antiviral therapy should be provided as soon as the viral infection is discovered; before that, the chronic antigenic stimulation determines the irreversible proliferation of neoplastic B cells...
August 2017: Clinics in Liver Disease
https://www.readbyqxmd.com/read/28675991/small-molecule-inhibitors-of-hepatitis-b-virus-nucleocapsid-assembly-a-new-approach-to-treat-chronic-hbv-infection
#16
Li Yang, Mengji Lu
Hepatitis B virus (HBV) infection is still a major health problem worldwide. The current available antiviral drugs for the treatment of chronic HBV infection do not achieve satisfactory results. Thus, it is desirable to develop novel anti-HBV drugs based the recent advances of basic research on molecular biology of HBV. HBV nucleocapsid assembly is now considered as a potential target of anti-HBV therapy. Structural and functional analysis provided essential insight of molecular interaction of the components of HBV nucleocapsid...
July 4, 2017: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/28675071/from-the-pathogenesis-to-the-cure-of-indolent-b-cell-lymphoproliferative-disorders-associated-with-hepatitis-c-virus-infection-which-role-for-direct-acting-antivirals
#17
Marcella Visentini, Massimo Fiorilli, Milvia Casato
Hepatitis C virus (HCV) causes monoclonal B cell lymphoproliferative disorders ranging from benign, such as in mixed cryoglobulinemia (MC), to indolent or aggressive lymphomas. MC and indolent lymphomas commonly regress when HCV is eradicated with interferon (IFN) therapy; however, sustained virologic response (SVR) to IFN is achieved only in ~50% of patients. The new all oral direct-acting antivirals (DAA), yielding nearly 100% SVR, promise a breakthrough in the treatment of HCV-associated lymphoproliferative disorders, but experience is still scanty...
July 4, 2017: Expert Review of Hematology
https://www.readbyqxmd.com/read/28669175/efficacy-of-tenofovir-based-rescue-therapy-for-chronic-hepatitis-b-patients-with-resistance-to-lamivudine-and-entecavir
#18
Hee-Jeong Jeon, Seok Won Jung, Neung Hwa Park, Yujin Yang, Jin-Hee Noh, Jae-Sung Ahn, Hyung Rae Kim, Jae Ho Lee, Jung Woo Shin
Background/Aims: Tenofovir disoproxil fumarate (TDF) monotherapy for 48 weeks provided a virological response comparable to that of TDF and entecavir (ETV) combination therapy in patients infected with ETV-resistant hepatitis B virus (HBV). Little long-term data in routine clinical practice are available regarding the optimal treatment of patients with ETV-resistant HBV. Methods: We investigated the long-term antiviral efficacy of combination therapy of TDF+lamivudine (LAM) or TDF+ETV compared to that of TDF monotherapy in 73 patients with resistance to both LAM and ETV...
June 30, 2017: Clinical and Molecular Hepatology
https://www.readbyqxmd.com/read/28668466/recommendations-for-screening-monitoring-prevention-prophylaxis-and-therapy-of-hepatitis-b-virus-reactivation-in-patients-with-haematological-malignancies-and-patients-who-underwent-haematological-stem-cell-transplantation-a-position-paper
#19
L Sarmati, M Andreoni, G Antonelli, W Arcese, R Bruno, N Coppola, G B Gaeta, M Galli, C Girmenia, M Mikulska, F Pane, C F Perno, M Picardi, M Puoti, A Rambaldi, V Svicher, G Taliani, G Gentile
SCOPE: Hepatitis B virus (HBV) infection reactivation is associated with high morbidity and mortality in patients with haematological malignancy and/or haematopoietic stem cell transplantation (HSCT) however information on this issue is limited. The scope of this position paper is to provide recommendations on HBV screening, monitoring, prophylaxis, treatment and vaccination in the patients described above. METHODS: - These recommendations were developed from one meeting of experts attended by different Italian scientific societies as well as from a systematic literature review (through December 31, 2016) on HBV infection in haematological patients and in patients who underwent HSCT published in the same issue of this journal...
June 28, 2017: Clinical Microbiology and Infection
https://www.readbyqxmd.com/read/28668465/screening-monitoring-prevention-prophylaxis-and-therapy-for-hepatitis-b-virus-reactivation-in-patients-with-haematological-malignancies-and-patients-who-underwent-haematological-stem-cell-transplantation-a-systematic-review
#20
REVIEW
G Gentile, M Andreoni, G Antonelli, L Sarmati
BACKGROUND: The growth of new therapeutic options and practices increases the risk of Hepatitis B virus (HBV) reactivation in patients with haematological malignancies and/or patients undergoing haematological stem cell transplantation (HSCT). OBJECTIVES: To provide a systematic review supporting recommendations for prevention, monitoring, prophylaxis and therapy of HBV reactivation in patients with haematological malignancies and HSCT. DATA SOURCES: The systematic review was based on a search strategy using PubMed and the Cochrane Library from 1991 to December 31(,) 2016...
June 28, 2017: Clinical Microbiology and Infection
keyword
keyword
32508
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"